Algernon Pharmaceuticals Inc. (AGNPF)
USD 0.05
(3.65%)
USD 0.05
(3.65%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 4.19 Million CAD | -48.49% |
| 2022 | 8.14 Million CAD | -19.7% |
| 2021 | 10.13 Million CAD | -20.95% |
| 2020 | 12.82 Million CAD | 140.23% |
| 2019 | 5.33 Million CAD | 275.16% |
| 2018 | 1.42 Million CAD | -13.06% |
| 2017 | 1.63 Million CAD | -28.0% |
| 2016 | 2.27 Million CAD | 62.23% |
| 2015 | 1.4 Million CAD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 3.95 Million CAD | -5.78% |
| 2024 Q3 | 3.89 Million CAD | -1.54% |
| 2024 Q2 | 3.95 Million CAD | 0.06% |
| 2023 FY | 4.19 Million CAD | -48.49% |
| 2023 Q3 | 6.13 Million CAD | 1.67% |
| 2023 Q2 | 6.03 Million CAD | -9.57% |
| 2023 Q4 | 4.19 Million CAD | -31.65% |
| 2023 Q1 | 6.67 Million CAD | -18.02% |
| 2022 Q4 | 8.14 Million CAD | 17.92% |
| 2022 FY | 8.14 Million CAD | -19.7% |
| 2022 Q3 | 6.9 Million CAD | -11.3% |
| 2022 Q2 | 7.78 Million CAD | -8.63% |
| 2022 Q1 | 8.51 Million CAD | -15.98% |
| 2021 FY | 10.13 Million CAD | -20.95% |
| 2021 Q1 | 10.23 Million CAD | -20.21% |
| 2021 Q3 | 11.62 Million CAD | 7.58% |
| 2021 Q2 | 10.8 Million CAD | 5.63% |
| 2021 Q4 | 10.13 Million CAD | -12.81% |
| 2020 Q3 | 14.45 Million CAD | 87.46% |
| 2020 Q4 | 12.82 Million CAD | -11.29% |
| 2020 FY | 12.82 Million CAD | 140.23% |
| 2020 Q1 | 6.8 Million CAD | 27.57% |
| 2020 Q2 | 7.71 Million CAD | 13.24% |
| 2019 FY | 5.33 Million CAD | 275.16% |
| 2019 Q3 | 5.63 Million CAD | -7.27% |
| 2019 Q1 | 6.46 Million CAD | 354.64% |
| 2019 Q2 | 6.07 Million CAD | -6.14% |
| 2019 Q4 | 5.33 Million CAD | -5.19% |
| 2018 FY | 1.42 Million CAD | -13.06% |
| 2018 Q1 | 1.44 Million CAD | -11.96% |
| 2018 Q4 | 1.42 Million CAD | -3.06% |
| 2018 Q2 | 1.65 Million CAD | 15.04% |
| 2018 Q3 | 1.46 Million CAD | -11.45% |
| 2017 FY | 1.63 Million CAD | -28.0% |
| 2017 Q3 | 1.91 Million CAD | -28.65% |
| 2017 Q1 | 3.08 Million CAD | 35.81% |
| 2017 Q2 | 2.68 Million CAD | -12.91% |
| 2017 Q4 | 1.63 Million CAD | -14.68% |
| 2016 Q3 | 2.62 Million CAD | -0.01% |
| 2016 Q1 | 2.88 Million CAD | 105.65% |
| 2016 FY | 2.27 Million CAD | 62.23% |
| 2016 Q4 | 2.27 Million CAD | -13.5% |
| 2016 Q2 | 2.62 Million CAD | -8.8% |
| 2015 FY | 1.4 Million CAD | 0.0% |
| 2015 Q4 | 1.4 Million CAD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Bioxytran, Inc. | 137.63 Thousand USD | -2946.905% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 89.205% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -5392.442% |
| SQZ Biotechnologies Company | 107.18 Million USD | 96.087% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -192.85% |
| Evofem Biosciences, Inc. | 10.55 Million USD | 60.264% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 96.779% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -5695.203% |
| Marizyme, Inc. | 22.01 Million USD | 80.951% |
| Genus plc | 1.02 Billion USD | 99.592% |
| Pharming Group N.V. | 462.85 Million USD | 99.094% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | -26.583% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -740.355% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -568.852% |
| ContraFect Corporation | 20.67 Million USD | 79.72% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -997.319% |
| IMV Inc. | 31.33 Million USD | 86.616% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | -1.15% |
| ONE Bio Corp. | 70.08 Million USD | 94.016% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 96.737% |
| Mesoblast Limited | 667.9 Million USD | 99.372% |
| MultiCell Technologies, Inc. | 126.22 USD | -3322431.295% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 88.079% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.876% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -444.181% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -1505.078% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | 41.914% |
| Biomind Labs Inc. | 73.81 Thousand USD | -5581.056% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -189.452% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 86.028% |
| Skye Bioscience, Inc. | 11.94 Million USD | 64.878% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -208.734% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | -52.702% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -974.299% |
| Arch Therapeutics, Inc. | 1.95 Million USD | -114.162% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -510.005% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -346.286% |
| EV Biologics, Inc. | 431.71 Thousand USD | -871.407% |
| Q BioMed Inc. | 3.51 Million USD | -19.291% |
| GB Sciences, Inc. | 103.44 Thousand USD | -3954.155% |
| Alpha Cognition Inc. | 2.45 Million USD | -71.02% |
| CSL Limited | 38.02 Billion USD | 99.989% |
| Agentix Corp. | 261.39 Thousand USD | -1504.372% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 99.06% |
| Enzolytics Inc. | 361.7 Million USD | 98.841% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Resverlogix Corp. | 8.11 Million USD | 48.322% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | -123.321% |
| MetaStat, Inc. | - USD | -Infinity% |
| Curative Biotechnology, Inc. | 2.6 Million USD | -61.098% |
| argenx SE | 4.54 Billion USD | 99.908% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 84.992% |
| HST Global, Inc. | 1526.00 USD | -274716.448% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 91.209% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -324.478% |
| Halberd Corporation | 10.13 Thousand USD | -41294.719% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -555.618% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | 53.139% |
| Zenith Capital Corp. | 7410.00 USD | -56495.128% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -18308.757% |
| GeneThera, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -1203.176% |
| AVAX Technologies, Inc. | 7.37 Million USD | 43.153% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -1504.543% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -351.926% |
| Ember Therapeutics, Inc. | 184.00 USD | -2279084.239% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | 62.24 Thousand USD | -6637.082% |
| Helix BioMedix, Inc. | 3.02 Million USD | -38.631% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 92.042% |
| Kadimastem Ltd | 2.3 Million USD | -82.012% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 14.56 Million USD | 71.198% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -7245.253% |
| Burzynski Research Institute, Inc. | 2310.00 USD | -181445.411% |
| LadRx Corporation | 2.3 Million USD | -81.712% |
| Cell Source, Inc. | 195.17 Thousand USD | -2048.731% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -772.675% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -1085.944% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -1085.944% |
| Affymax, Inc. | 7.44 Million USD | 43.656% |
| Mobile Lads Corp. | 52.00 USD | -8064705.769% |
| Itoco Inc. | 1.4 Million USD | -199.535% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -4284.1% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -3856.32% |
| International Stem Cell Corporation | 5.39 Million USD | 22.195% |
| CytoDyn Inc. | 11.13 Million USD | 62.341% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -2833.231% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -23354.692% |
| Qrons Inc. | 420.00 USD | -998399.762% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -987.942% |
| SYBLEU INC | 330.46 Thousand USD | -1169.018% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -659.563% |
| Rebus Holdings, Inc. | 5000.00 USD | -83773.98% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -924.297% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | 72.045% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | 74.705% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -5208.48% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -385.002% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | 44.21% |
| Neutra Corp. | 2851.00 USD | -146995.721% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 87.059% |
| PureTech Health plc | 693.97 Million USD | 99.396% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | 48.04% |
| IXICO plc | 15.84 Million USD | 73.531% |
| IntelGenx Technologies Corp. | 8.28 Million USD | 49.364% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 95.941% |
| CSL Limited | 38.02 Billion USD | 99.989% |
| Cellectis S.A. | 333.99 Million USD | 98.744% |